• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
RPRX

RPRX

Royalty Pharma plc

NASDAQHealthcareBiotechnologyUS

USD54.97

+0.96 (+1.78%)

Rating:B+

Company Profile

CEO

Pablo Legorreta

IPO Date

2020-06-16

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$54.15

Prev. Close

$54.01

Day Low

$53.97

Day High

$55.51

52W Low

$33.25

52W High

$56.07

Market Cap

$23.64B

Volume

4.39M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

39.3%

Avg Negative

11.4%

Avg Neutral

49.3%

News Feed

Royalty Pharma Declares Third-Quarter 2021 Dividend

GlobeNewsWire·7/16/2021·↑ positive

Royalty Pharma Announces Pricing of $1.3 Billion of Senior Unsecured Notes, Including $600 Million Social Bond

GlobeNewsWire·7/15/2021·↑ positive

Royalty Pharma Insights: Return On Capital Employed

Benzinga·6/2/2021·↓ negative

MorphoSys to Acquire Constellation Pharma at $34/Share; Enters $2B Strategic Funding with Royalty Pharma

Benzinga·6/2/2021·↑ positive

Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys

GlobeNewsWire·6/2/2021·↑ positive

Royalty Pharma plc (RPRX) CEO Pablo Legorreta on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/11/2021·↓ negative

Royalty Pharma to Announce First-Quarter 2021 Financial Results on May 11, 2021

GlobeNewsWire·4/21/2021·↓ negative

Royalty Pharma Announces Strategic Alliance With MSCI to Launch Life Sciences Indexes

GlobeNewsWire·4/21/2021·↑ positive

Royalty Pharma Declares Second-Quarter 2021 Dividend

GlobeNewsWire·4/15/2021·↑ positive

SYF or RPRX: Which Is the Better Value Stock Right Now?

Zacks Investment Research·4/12/2021·↑ positive